Temperature-dependent solubilization and thermodynamic characteristics of ribociclib in varied {PEG 400 + water} combinations

Authors: Faiyaz Shakeel, Ramadan Al-Shdefat, Mohammad Ali, Usama Ahmad

Source: BMC Chemistry, Vol 19, Iss 1, Pp 1-13 (2025)

Subject Terms: Computational validation, Dissolution, {PEG 400 + water} mixtures, Ribociclib, Solubility, Thermodynamics, Chemistry, QD1-999

File Description: electronic resource

Relation: https://doaj.org/toc/2661-801X

Access URL: https://doaj.org/article/96f16d3db9be4b7e8b11b32d29758b4c

Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy

Authors: Stefanos Ioannis Moukas, Merle Dohn, Catrin Lehnerdt, Anja Welt, Hans-Christian Kolberg, Oliver Hoffmann, Rainer Kimmig, Sabine Kasimir-Bauer, Corinna Keup

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-15 (2025)

Subject Terms: Thymidine kinase 1, Progression-free survival, Breast cancer, Ribociclib, Palbociclib, Longitudinal studies, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/d83cbfbe70f248e7ab263ec1cc613c5a

Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer

Authors: Al-Batsh T, Abdel-Razeq N, Al-Masri Y, El-Khatib O, Sharaf B, Tamimi F, Abdel-Razeq H

Source: Biologics: Targets & Therapy, Vol Volume 19, Pp 97-111 (2025)

Subject Terms: breast cancer, endocrine therapy, ovarian function suppression, cdk4/6 inhibitors, abemaciclib, ribociclib, aromatase inhibitors, tamoxifen, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.dovepress.com/escalation-and-de-escalation-strategies-for-endocrine-therapy-in-early-peer-reviewed-fulltext-article-BTT; https://doaj.org/toc/1177-5491

Access URL: https://doaj.org/article/fa47767dd1ce401da3bce85e409cf7df

Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast

Authors: Abhira Deb, Manthan Dhingra, Srutee Barman, Thinakaran Raja, Abhra Ghosh

Source: Journal of the Egyptian Women’s Dermatologic Society, Vol 22, Iss 1, Pp 88-91 (2025)

Subject Terms: breast cancer, cyclin-dependent kinase 4/6 inhibitors, ribociclib, vitiligo, Dermatology, RL1-803

File Description: electronic resource

Relation: https://journals.lww.com/10.4103/jewd.jewd_64_24; https://doaj.org/toc/2090-2565

Access URL: https://doaj.org/article/b0a82198fc7a424c817ee5e2c08c9e35

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments

Authors: Zihan Liu, Wenyu Du, Qimin Wang, Zhi Wang, Jing An, Yinling Ma, Zhanjun Dong, Ying Li

Source: Frontiers in Pharmacology, Vol 16 (2025)

Subject Terms: cancer-associated venous thromboembolism, drug-drug interaction, ribociclib, apixaban, rivaroxaban, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2025.1530806/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/c3f2b3df49004254a0a219e20f1e2c5c

A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer

Authors: Jialin Zhang, Xinyu Xu, Yeyue Zhou, Jingyang Su, Jue Wang

Source: Frontiers in Oncology, Vol 15 (2025)

Subject Terms: breast cancer, CDK4/6 inhibitors, Abemaciclib, Palbociclib, Ribociclib, Dalpiciclib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2025.1472407/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/6b582a1df25b4e2d8f392d63c2c5ce8e

RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway

Authors: Zhidong Huang, Kaixin Lou, Mengyang Qi, Jinhui Wang, Linwei Li, Bo Sun, Chen Wang, Xirui Zhou, Debo Chen, Hong Liu

Source: Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-16 (2024)

Subject Terms: Breast cancer, CDK4/6 inhibitor, Ribociclib, LncRNA, Machine learning algorithm, Malignant phenotype, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/1479-5876

Access URL: https://doaj.org/article/9a7d5eea1e1c477ea592e45205347318

Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country

Authors: Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T

Source: ImmunoTargets and Therapy, Vol Volume 13, Pp 501-512 (2024)

Subject Terms: metastatic breast cancer, mbc, cdk4/6 inhibitors, ribociclib, aromatase inhibitors, fulvestrant, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://www.dovepress.com/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-peer-reviewed-fulltext-article-ITT; https://doaj.org/toc/2253-1556

Access URL: https://doaj.org/article/a11cfe5e6ffa41b2b2eca6ea7b3bc8f7

Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume

Authors: Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, Ergin Aydemir, İrem Öner, Öztürk Ateş, Cengiz Karaçin

Source: Current Oncology, Vol 31, Iss 10, Pp 5722-5729 (2024)

Subject Terms: mean corpuscular volume, CDK4/6, palbociclib, ribociclib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/31/10/424; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/a433ba64f8604e4fafa1869340c79037

Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty

Authors: Niraula, Saroj

Source: In Cancer Treatment Reviews May 2025 136

Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports

Authors: Tamara Martos, Marta Saint-Gerons, Laura Masfarre, Maria Castro-Henriques, Maria Martinez-Garcia, Sonia Servitja, Joan Albanell

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: palinopsias, ribociclib, breast cancer, adverse events, ophthalmologic toxicity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1430341/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/f409450883894664966125fcbed44822

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting

Authors: Marcin Kubeczko, Anna Polakiewicz-Gilowska, Andrea D’Amico, Olgierd Chrabański, Katarzyna Świderska, Ewa Chmielik, Sławomir Blamek, Daria Handkiewicz-Junak, Michał Jarząb

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: advanced breast cancer, 18Ffluorodeoxyglucose positron emission tomography, palbociclib, ribociclib, abemaciclib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1454844/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/9d9e1f7a93a64468bcf194119069923b

The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials

Authors: Merve Keskinkilic, Mehmet Emin Arayici, Yasemin Basbinar, Hulya Ellidokuz, Tugba Yavuzsen, Ilhan Oztop

Source: Breast, Vol 78, Iss , Pp 103815- (2024)

Subject Terms: Palbociclib, Ribociclib, Abemaciclib, Meta-analysis, CDK4/6 inhibitor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0960977624001462; https://doaj.org/toc/1532-3080

Access URL: https://doaj.org/article/330e286730524e79849f3b4010a9a9bd

Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome

Authors: Po-Jen Chen, Shun-Hua Chen, Yu-Li Chen, Yi-Hsuan Wang, Cheng-Yu Lin, Chun-Hong Chen, Yung-Fong Tsai, Tsong-Long Hwang

Source: Journal of Advanced Research, Vol 62, Iss , Pp 229-243 (2024)

Subject Terms: Acute respiratory distress syndrome, Ribociclib, Neutrophilic inflammation, Phosphodiesterase 4, Medicine (General), R5-920, Science (General), Q1-390

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S209012322400119X; https://doaj.org/toc/2090-1232

Access URL: https://doaj.org/article/253e57a5843748d2a16b88013cc43780

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

Authors: Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)

Subject Terms: Breast cancer, Palbociclib, Ribociclib, Propensity score matching, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/5b0a3d9bcc4b42bca28dd69de26ddc68

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III

Authors: Nicola Battelli, Carmela Mocerino, Michele Montedoro, Mirco Pistelli, Ilaria Portarena, Mario Rosanova, Tina Sidoni, Patrizia Vici

Source: Current Oncology, Vol 32, Iss 4, p 192 (2025)

Subject Terms: breast cancer, adjuvant therapy, ribociclib, stage II, stage III, adherence, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/32/4/192; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/b8e1b97e1d2b4e92934034963da8e5e3

Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer

Authors: Tugay Avci, Mustafa Sahbazlar, Ferhat Ekinci, Atike Pinar Erdogan

Source: Current Oncology, Vol 32, Iss 3, p 161 (2025)

Subject Terms: metastatic breast cancer, palbociclib, ribociclib, CDK 4/6 inhibitors, fulvestrant, letrozol, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/32/3/161; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/a6c3d50b09724ec7be7e9cc5b0e07472

Voltammetric detection of ribociclib in cancer therapy using glassy carbon electrode and boron-doped diamond electrode

Authors: Aslan, Mehmet ^a, Aslan, Yaşar ^b, Levent, Abdulkadir ^{b, ⁎}

Source: In Diamond & Related Materials February 2025 152

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Authors: Hortobagyi, G.N. ^{1, ∗}, Lacko, A. ², Sohn, J. ³, Cruz, F. ⁴, Ruiz Borrego, M. ⁵, Manikhas, A. ⁶, Hee Park, Y. ⁷, Stroyakovskiy, D. ⁸, Yardley, D.A. ⁹, Huang, C.-S. ¹⁰, Fasching, P.A. ¹¹, Crown, J. ¹², Bardia, A. ¹³, Chia, S. ¹⁴, Im, S.-A. ¹⁵, Martin, M. ¹⁶, Loi, S. ¹⁷, Xu, B. ¹⁸, Hurvitz, S. ¹⁹, Barrios, C. ²⁰, Untch, M. ²¹, Moroose, R. ²², Visco, F. ²³, Parnizari, F. ²⁴, Zarate, J.P. ²⁵, Li, Z. ²⁵, Waters, S. ²⁶, Chakravartty, A. ²⁵, Slamon, D. ¹³

Source: In Annals of Oncology February 2025 36(2):149-157

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study

Authors: Bianchini, G. ^{1, 2}, Munzone, E. ³, Marra, A. ⁴, Boldrini, L. ^{4, 5}, Carnevale Schianca, A. ^{4, 5}, Katrini, J. ^{4, 5}, Cona, M.S. ⁶, Cantile, V. ⁷, Grieco, A. ⁷, Pirolo, M. ⁷, Zappulo, M. ⁷, De Giglio, M.A.R. ⁷, Laganà, M. ⁸, Cosentini, D. ⁸, De Giorgi, U. ⁹, Vingiani, A. ^{5, 10}, Belfiore, A. ¹⁰, Fotia, G. ^{5, 11}, Mazzoli, G. ^{5, 11}, Sposetti, C. ^{5, 11}, Abate, A. ¹¹, Bianchessi, V. ¹¹, Capri, G. ¹¹, Bianchi, G.V. ¹¹, de Braud, F. ^{5, 11}, Baili, P. ¹², Scaperrotta, G. ¹³, Depretto, C. ¹³, Lasagna, A. ¹⁴, Jacobs, F. ¹⁵, Ponzoni, O. ¹⁶, Maccarone, S. ¹⁷, Strina, C. ¹⁸, Coccato, S. ¹⁹, Coviello, R. ²⁰, Provenzano, L. ^{1, 2}, Dieci, M.V. ^{3, 4}, Curigliano, G. ^{5, 6}, Giuliano, M. ⁷, Botticelli, A. ⁸, Lambertini, M. ^{9, 10}, Rizzo, G. ¹¹, Pedersini, R. ¹², Sirico, M. ¹³, La Verde, N. ¹⁴, Gennari, A. ^{15, 16}, Zambelli, A. ^{17, 18}, Toss, A. ^{19, 20}, Piras, M. ²¹, Giordano, M. ²², Tagliaferri, B. ²³, Generali, D. ^{24, 25}, Sartori, D. ²⁶, Miliziano, D. ^{1, 5}, Menichetti, A. ³, Ligorio, F. ^{1, 2}, Zurlo, C. ^{3, 4}, Griguolo, G. ^{3, 4}, Berton Giachetti, P.P. ^{5, 6}, Faso, V. ^{3, 4}, Corti, C. ^{5, 6}, Chiappe, E. ^{9, 10}, Scagnoli, S. ⁸, Pisegna, S. ^{27, 28}, Capasso, C. ⁸, De Angelis, C. ⁷, Arpino, G. ⁷, Criscitiello, C. ^{5, 6}, Guarneri, V. ^{3, 4}, Pruneri, G. ^{5, 29}, Mariani, L. ³⁰, Vernieri, C. ^{1, 5, ∗}

Source: In Annals of Oncology